Consolidated Statements of Cash Flows (USD $)	3 Months Ended		134 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Cash flows from operating activities
Net loss	$ (3,655,574)	$ (4,177,482)	$ (129,923,519)
Adjustments to reconcile net loss to net cash used in operating activities
Stock payable for acquired research and development			112,440
Stock issued for acquired research and development			26,286,589
Stock issued for services			1,993,182
Restricted stock issued to employees	100,176		238,636
Stock issued for debt in excess of principal			109,070
Amortization of discount on notes payable due to warrants and beneficial conversion feature		1,237,662	8,470,084
Loss on extinguishment of debt			906,472
Depreciation	95,586	78,311	2,081,341
Amortization of debt financing costs		52,939	708,265
Option and warrant expense	331,031	411,187	17,726,604
(Gain) loss on derivative instruments			(1,941,826)
Loss on disposition of fixed assets			515,506
Changes in:
Other current assets	(425,605)	(115,589)	(1,474,607)
Accounts payable - third parties and related parties	(12,614)	418,562	(25,342)
Accrued expenses	(4,323)	457,240	1,529,464
Other assets	11,017	(104,027)	(166,650)
Deferred revenue	(348,837)	4,779,900	3,384,552
Net cash provided by (used in) operating activities	(3,909,143)	3,038,703	(69,469,739)
Cash flows from investing activities
Purchase of property & equipment	(75,874)	(2,598)	(2,557,297)
Restricted cash		500,000
Net cash provided by (used in) investing activities	(75,874)	497,402	(2,557,297)
Cash flows from financing activities
Common stock and warrants sold for cash, net of offering costs		3,623,738	77,938,675
Common stock repurchased and canceled			(325)
Proceeds from exercise of warrants and options			1,248,588
Deferred financing and offering costs		(17,511)	(657,339)
Repayments on notes payable		(450,000)	(761,222)
Net cash provided by financing activities		3,706,227	91,686,561
Net change in cash and cash equivalents	(3,985,017)	7,242,332	19,659,525
Cash and cash equivalents at beginning of period	23,644,542	592,004
Cash and cash equivalents at end of period	19,659,525	7,834,336	19,659,525
Cash paid for:
Income tax
Interest		18,647	174,757
NON-CASH TRANSACTIONS
Issuance of common stock to Sportan shareholders			147,733
Issuance of common stock for accrued interest			977,830
Issuance of warrants to placement agent			37,453
Conversion of notes payable and accrued interest to common stock		1,000,000	11,985,033
Conversion of accrued liabilities to common stock			197,176
Conversion of accounts payable to note payable			93,364
Discount on convertible notes relating to:
Warrants		195,969	6,170,341
Beneficial conversion feature		141,829	3,444,982
Stock attached to notes			1,287,440
Fair value of derivative instrument			4,680,220
Derivative reclassified to equity			2,349,266
Unpaid additions to property and equipment	14,311		122,827
Amortization of deferred offering costs to paid-in capital		45,450	47,339
Shares issued as deferred offering costs		1,234	150,365
Unpaid offering costs	17,467		17,467
Third Parties
Cash flows from financing activities
Proceeds from convertible debt		550,000	13,288,184
Related Parties
Cash flows from financing activities
Proceeds from convertible debt		100,000	730,000
Repayments on notes payable		$ (100,000)	$ (100,000)